Form 4 for ONC BeOne Medicines Ltd.
Accepted 2025-02-20 00:00:00 ET · period of report 2025-02-18 · accession 0001651308-25-000018 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-20 | 2025-02-18+ | ONC | Wu Xiaobin | Pres, COO, GM China | S - Sale+OE | $240.46 | -51.9K | 11.1K | -82% | -$12.49M |
| DM | 2025-02-20 | 2025-02-18+ | ONC | Wu Xiaobin | Pres, COO, GM China | M - OptEx | $169.65 | +51.9K | 30.7K | New | +$8.81M |
| DM | 2025-02-20 | 2025-02-18+ | ONC | Wu Xiaobin | Pres, COO, GM China | M - OptEx | $0.00 | -675.0K | 368.1K | -65% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | American Depositary Shares | 2025-02-20 | S | D | 21,267 | $240.07 | 0 | D | — | — | (F1) Each American Depositary Share represents 13 Ordinary Shares. (F9) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.00 to $240.50, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. |
| 2 | Common | American Depositary Shares | 2025-02-20 | M | A | 21,267 | $169.65 | 21,267 | D | — | — | (F1) Each American Depositary Share represents 13 Ordinary Shares. |
| 3 | Common | American Depositary Shares | 2025-02-18 | S | D | 7,919 | $241.26 | 3,159 | D | — | — | (F1) Each American Depositary Share represents 13 Ordinary Shares. (F7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $241.00 to $241.96, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. |
| 4 | Common | American Depositary Shares | 2025-02-18 | S | D | 3,159 | $242.08 | 0 | D | — | — | (F1) Each American Depositary Share represents 13 Ordinary Shares. (F8) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.00 to $242.28, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. |
| 5 | Common | American Depositary Shares | 2025-02-18 | S | D | 19,576 | $240.31 | 11,078 | D | — | — | (F1) Each American Depositary Share represents 13 Ordinary Shares. (F6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.00 to $240.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. |
| 6 | Common | American Depositary Shares | 2025-02-18 | M | A | 30,654 | $169.65 | 30,654 | D | — | — | (F1) Each American Depositary Share represents 13 Ordinary Shares. |
| 7 | Derivative | Share Option (Right to Buy) | 2025-02-20 | M | D | 276,471 | $0.00 | 91,626 | D | $13.05 · — to 2028-04-29 | 276,471 Ordinary Shares | (F10) The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares. (F11) These securities vest over a five-year period as follows: 20% on April 30, 2019, and the remaining in 48 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events. |
| 8 | Derivative | Share Option (Right to Buy) | 2025-02-18 | M | D | 398,502 | $0.00 | 368,097 | D | $13.05 · — to 2028-04-29 | 398,502 Ordinary Shares | (F10) The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares. (F11) These securities vest over a five-year period as follows: 20% on April 30, 2019, and the remaining in 48 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events. |